shape therapeutics leadership team

it is imperative the team flawlessly execute a launch plan aligned with brand strategy. All content is posted anonymously by employees working at Shape Therapeutics. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . See what employees say it's like to work at Shape Therapeutics. Shape Therapeutics, Inc. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Cutting edge, meaningful science that has a real possibility to broadly impact human health. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. All rights reserved. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Glad that you want to get updates from Shape Therapeutics. Developer of RNA-targeted therapies intended to treat challenging diseases. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Interested in what they do or partnership? We have to be creative; we need to transform the paradigm. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. As Doug noted, our full year net product revenue was $843.8 million . Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Last Funding Type Series B. Operator. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Shape Therapeutics's is . ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. 2023 Sarepta Therapeutics, Inc. All rights reserved. . We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. site you are consenting to these choices. At this time, all participants are in a listen-only mode . Working at Shape has been great! cindy@shaptetx.com, 1985 - 2023 BioSpace.com. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Also Known As ShapeTX. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Im thrilled to join such a talented team of innovative thinkers. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. 69% of the management team is White. And I don't just mean the science but also on healthcare policy. We know why we get up every day and work as hard as we do. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. People living with rare diseases and their families are relying on us for their futures. ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. Shape Therapeutics's Vice President, Head of Research is David Huss. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. You can find us at shapetx.com and on LinkedIn and Twitter. Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. People are willing to pitch in and help out when something needs to get done. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. 2023 PitchBook. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Shape Life! SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Learn more. Up to 5 Cindy Fung, PhD David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. Our Commitment to Diversity. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. | Source: Engineering best-in-class. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. ProQR Therapeutics At Sarepta, I have found that every voice matters, respect matters and building trust matters all of these contribute to an organization that is poised to transform the lives of patients. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. July 15, 2021 08:00 ET Highlight your management teams expertise. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Its very rewarding. Co-Founder, President & CEO, Patrick Bigot Boston, MA 02111. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Do you excel more in a team or individual setting? What is health insurance like at Shape Therapeutics? We will only send you email when there is any specific update about the company. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Copyright 2023 CB Information Services, Inc. All rights reserved. There isnt a path to guide us. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry Powered by Madgex Job Board Software. 11 Shape Therapeutics reviews. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. They seem respectful towards one another. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. . Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. We [] We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? People. ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. A free inside look at company reviews and salaries posted anonymously by employees. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Sign up for a free account. The net loss for the full . Shape Therapeutics's key executives include David Huss and 11 others. ", I feel this real connection to the patients were having an impact on. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. All rights reserved. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. It focuses on RNA-editing gene therapy. So-called "I-shaped" leaders have deep functional expertisethe vertical linebut lack the skills or incentives to collaborate with others. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Investors & Media So far, I like the team. Get the full list, Youre viewing 5 of 9 board members. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Meet members of our executive team at StrideBio. Get the full list, Youre viewing 5 of 10 investors. Shape Therapeutics, Inc. employs 14 employees. {{ userNotificationState.getAlertCount('bell') }}. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Lorem ipsum dolor sit amet consectetur adipisicing elit. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Shape Life! The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. | Source: Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Shape Therapeutics is a development-stage biotechnology company. Headquarters Location 219 Terry Ave N Suite 100 Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Great team culture. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Discover current leadership team members including founders, CEO, other executives and board directors. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . CBI websites generally use certain cookies to enable better interactions with. 11 Shape Therapeutics reviews. ", Im here to bring genetic medicine to life. Enter employee name to find & verify emails, phones, social links, etc. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . . I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. million verified professionals across 35 million companies. You can read more about your. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Shape Life! ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Search over 700 I cannot imagine being anyplace else.". She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Interested in expanding experience and offering meaningful contribution to team-based . A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. We have plenty of data and we can help. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Shape Therapeutics is . ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Im thrilled to join such a talented team of innovative thinkers. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Personalize which data points you want to see and create visualizations instantly. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Existing Subscriber? Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. Founded Date Apr 5, 2018. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Type Private Status Active Founded 2018 HQ Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Shape Therapeutics has 5 executives. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Shape Therapeutics, Inc. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. You can read more about your cookie choices at our privacy policyhere. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Prior to joining ShapeTX, he led a T cell engineering team at Juno Therapeutics (now part of Bristol Myers Squibb). 10% of PTC Therapeutics management is Hispanic or Latino. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. April 20, 2021 08:00 ET Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer.

Nahshon Wright Family, Mass General Jobs In Salem, Nh, Masterchef Courtney And Joe, Raw Vegan Life Expectancy, Articles S